ParvOryx01: Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme

TRAVERSE: A Phase 2b randomized open-label trial of JX-594 (Vaccinia GM-CSF/TK-deactivated virus) in Patients with advanced hepatocellular carcinoma who have failed sorafenib treatment.

ParvOryx02: A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer.

TVEC 325: A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated With Talimogene Laherpa

MASTERKEY-265: A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma.

PHOCUS: Hepatocellular Carcinoma Study (Phase III) Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

V937-013: A Phase 1b/2 Study of Intratumoral Administration of CVA21 in Combination with Pembrolizumab for Treatment of Advanced Solid Tumors

GOBLET: A phase I/II multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab

START: Safety and anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer